Novartis news

Sandoz receives positive EU opinion for biosimilar filgrastim

in

Rasilez HCT® receives recommendation for European approval as a single-pill combination to treat high blood pressure

in

Novartis highlights innovative approach to drug discovery with dynamic advance in exploratory pipeline

in

Rasilez®, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older

in

Rasilez HCT®, single-pill combination of Rasilez® and diuretic, receives Swiss approval for the treatment of high blood pressure

in

ACZ885 Phase III data show rapid, sustained clinical remission in children and adults suffering from a group of rare, potentially life-threatening autoinflammatory diseases

in

Novartis to acquire Nektar Therapeutics pulmonary business unit, strengthening respiratory drug delivery capabilities

in

Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals

in

Early data show

in

Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease

New Phase II

in

New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium